Successful Danish biotech company Genmab (Nasdaq: GMAB) said late Friday that its chairman, Mats Pettersson, has decided to step down from the post on March 26, when his election period expires.
Mr Pettersson has led the company’s board of directors since his election in 2013 and will not be up for re-election at the company’s 2020 Annual General Meeting.
“I am extremely grateful to Mats for his strong leadership as chairman and for his service in overseeing our goals and strategies and monitoring our business performance over the last seven years,” said Jan van de Winkel, chief executive of Genmab, adding: “On behalf of the entire board of directors and the executive management team, I’d like to thank Mats for his excellent contributions and wish him continued success.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze